Diazoxide choline extended‐release tablet in people with Prader‐Willi syndrome: results from long‐term open‐label study
Obesity · 2024-02 · 32 (2) · 252-261
DOI: 10.1002/oby.23928 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, online erschienen am 02.11.2023. Verfasst von Jennifer L Miller und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Prader-Willi Syndrome. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Soleno Therapeutics, Intramural NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Objective
This study assessed the effect of 1‐year administration of diazoxide choline extended‐release tablet (DCCR) on hyperphagia and other complications of Prader‐Willi syndrome (PWS).
Methods
The authors studied 125 participants with PWS, age ≥ 4 years, who were enrolled in the DESTINY PWS Phase 3 study and who received DCCR for up to 52 weeks in DESTINY PWS and/or its open‐label extension. The primary efficacy endpoint was Hyperphagia Questionnaire for Clinical Trials (HQ‐CT) score. Other endpoints included behavioral assessments, body composition, hormonal measures, and safety.
Results
DCCR administration resulted in significant improvements in HQ‐CT (mean [SE] −9.9 [0.77], p < 0.0001) and greater improvements in those with more severe baseline hyperphagia (HQ‐CT > 22). Improvements were seen in aggression, anxiety, and compulsivity (all p < 0.0001). There were reductions in leptin, insulin, and insulin resistance, as well as a significant increase in adiponectin (all p < 0.004). Lean body mass was increased ( p < 0.0001). Disease severity was reduced as assessed by clinician and caregiver (both p < 0.0001). Common treatment‐emergent adverse events included hypertrichosis, peripheral edema, and hyperglycemia. Adverse events infrequently resulted in discontinuation (7.2%).
Conclusions
DCCR administration to people with PWS was well tolerated and associated with broad‐ranging improvements in the syndrome. Sustained administration of DCCR has the potential to reduce disease severity and the burden of care for families.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida, USA.
- Queen Mary University of London, Barts Health NHS Trust-Royal London Children's Hospital, London, UK.
- Chelsea and Westminster Hospital, London, UK.
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
- Seattle Children's Hospital, Seattle, Washington, USA.
- Nationwide Children's Hospital, Columbus, Ohio, USA.
ORCID-Profile: Nicola Bridges, Jack A Yanovski, Neil M Cowen
Förderung
- Soleno Therapeutics
- Intramural NIH HHS
- NICHD NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Miller, J. L., Gevers, E., Bridges, N., Yanovski, J. A., Salehi, P., Obrynba, K. S., Felner, E. I., Bird, L. M., Shoemaker, A. H., Angulo, M., Butler, M. G., Stevenson, D., Goldstone, A. P., Wilding, J., Lah, M., Shaikh, M. G., Littlejohn, E., Abuzzahab, M. J., Fleischman, A., …, & C601/C602 Investigators (2024). Diazoxide choline extended‐release tablet in people with Prader‐Willi syndrome: results from long‐term open‐label study. Obesity, 32(2), 252-261. https://doi.org/10.1002/oby.23928
Vancouver
Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, et al. Diazoxide choline extended‐release tablet in people with Prader‐Willi syndrome: results from long‐term open‐label study. Obesity. 2024;32(2):252-261. doi:10.1002/oby.23928
BibTeX
@article{Miller2024,
author = {Miller, Jennifer L and Gevers, Evelien and Bridges, Nicola and Yanovski, Jack A and Salehi, Parisa and Obrynba, Kathryn S and Felner, Eric I and Bird, Lynne M and Shoemaker, Ashley H and Angulo, Moris and Butler, Merlin G and Stevenson, David and Goldstone, Anthony P and Wilding, John and Lah, Melissa and Shaikh, M Guftar and Littlejohn, Elizabeth and Abuzzahab, M Jennifer and Fleischman, Amy and Hirano, Patricia and Yen, Kristen and Cowen, Neil M and Bhatnagar, Anish and C601/C602 Investigators, C601/C602 Investigators},
title = {Diazoxide choline extended‐release tablet in people with Prader‐Willi syndrome: results from long‐term open‐label study},
journal = {Obesity},
year = {2024},
volume = {32},
number = {2},
pages = {252--261},
doi = {10.1002/oby.23928}
}
EUVIMED